Purpose: To assess and quantify teprotumumab’s effect on thyroid eye disease-related strabismus by change in measured horizontal and vertical deviations and change in extraocular motility. Methods: We reviewed a series of patients with thyroid eye disease-related strabismus treated with teprotumumab. Exclusion criteria included age under 18 years, strabismus of alternate etiology, or thyroid eye disease-related reconstructive surgery during the treatment course. Primary outcomes were absolute (prism diopters) and relative (%) differences in horizontal and vertical deviations in primary position at distance, as well as change in ductions of the more affected eye. Secondary outcomes included incidence and timing of strabismus surgery postteprotumumab. Results: Thirty-one patients were included, with mean age 63 years and thyroid eye disease duration 10 months. After teprotumumab, there was 6 prism diopters (39%) mean reduction in vertical deviation (p < 0.001), without significant change in mean horizontal deviation (p = 0.75). Supraduction, abduction, adduction, and infraduction significantly improved in the more restricted eye (p < 0.01, p < 0.01, p = 0.04, and p = 0.01, respectively). Thirty-five percent of patients underwent strabismus surgery posttreatment, at an average 10 months after last infusion. Conclusions: Teprotumumab produced a statistically significant reduction in vertical but not horizontal strabismus angles in primary position at distance. Extraocular motility in all 4 ductions also improved. A substantial minority of patients still required strabismus surgery following teprotumumab.
9 May 2024 in Ophthalmic Plastic & Reconstructive Surgery
Purpose: This study evaluates the efficacy of teprotumumab in reducing eyelid retraction in thyroid eye disease (TED) patients. Methods: This retrospective study included patients with active or chronic moderate-to-severe TED who completed at least 4 cycles of teprotumumab. Patients with upper and/or lower eyelid retraction, defined as margin-to-reflex distance (MRD) 1 and/or MRD2 of more than 5 mm, in one or OU were included. The main outcome measure was a change in MRD1 and MRD2 after treatment. Changes in MRD1 and MRD2 were each analyzed for correlation (r) with changes in exophthalmolmetry. Student t test was performed for each comparison, and p values <0.05 were considered significant. Results: The study included 91 patients, predominantly female (87%), with an average age of 52.02 ± 14.6 years. The mean baseline proptosis measurement was 21.8 ± 2.9 OD and 21.7 ± 3.3 OS. The average MRD1 was 5.5 ± 1.5 OD and 5.4 ± 1.7 OS, and the average MRD2 was 6.1 ± 1.1 OD and 6.2 ± 1.1 OS. The follow-up duration post-treatment was 37.5 ± 31.7 weeks. At first follow-up post-treatment, the mean change in proptosis, MRD1, and MRD2 were −2.6 ± 2.0 OD, −2.5 ± 2.1 OS, −0.8.5 ± 1.4 OD, −0.8 ± 1.0 OS, and −0.7 ± 0.9 OD, −0.8 ± 1.0 OS, respectively. Correlation analysis showed that proptosis reduction was positively correlated with MRD1 and MRD2 reduction at the first post-treatment follow-up (MRD1: r = 0.23, p value < 0.01; MRD2: r = 0.17, p = 0.03]. Conclusion: Teprotumumab treatment improves upper and lower eyelid retraction. The improvement in MRD correlated positively with proptosis reduction, indicating the influence of globe position on eyelid position.
20 December 2024 in Ophthalmic Plastic & Reconstructive Surgery
Purpose: The authors aimed to describe and characterize shortened fornix syndrome (SFS), a rare complication following posterior-approach ptosis repair using conjunctival Müller muscle resection. Methods: This retrospective case series evaluates 4 patients who developed SFS after conjunctival Müller muscle resection. Clinical characteristics, surgical histories, management, and outcomes are reviewed. Results: A total of 4 patients (2 females, 2 males; aged 61–74 years old) presented with ptosis associated with fornix shortening and symblepharon following conjunctival Müller muscle resection performed at outside hospitals. Potential contributing factors included intraoperative complications and multiple posterior-approach surgeries. Management strategies varied, including 5-fluorouracil and triamcinolone injections into the symblepharon, ocular surface reconstruction with symblepharon lysis and amniotic membrane grafting, and external levator advancement. All patients showed improvement in the SFS and eyelid height with treatment. Conclusion: SFS, characterized by symblepharon, fornix shortening, and associated functional issues including ptosis and restricted eye movements, is a rare but significant complication of posterior-approach ptosis repair. Only one prior report has documented a similar entity in patients after conjunctival Müller muscle resection using glaucoma drops; interestingly, the authors’ cases occurred in patients without significant ocular surface or topical ocular medication use, suggesting SFS can develop independently of such treatments. Prevention strategies include meticulous intraoperative technique and a cautious approach to large resections or repeat posterior-based surgeries, with consideration of anterior-based techniques if appropriate. Management of SFS via a staged approach involving ocular surface reconstruction followed by anterior-based ptosis repair may lead to satisfactory outcomes. Awareness of this complication is crucial for proper patient selection and management of ptosis.
To evaluate the effects of teprotumumab on individual extraocular muscle (EOM) volume and proptosis in thyroid eye disease (TED). A retrospective review was performed using exophthalmometry, clinical activity score (CAS), and orbital imaging before and after teprotumumab treatment. The lateral rectus (LR), medial rectus (MR), superior rectus (SR), inferior rectus (IR) muscles, and the globe were manually segmented individually. Individual and total EOM volumes were calculated and compared between pre- and post-treatment magnetic resonance imaging (MRI). Mean proptosis reduction after teprotumumab treatment was 3.69 mm (95% CI: 2.82, 4.17, p < 0.001), with an improvement in all orbits. Significant muscle volume reductions occurred in the MR (-20%, p < 0.001) and IR (-28%, p = 0.002) but not the LR (-11%, p = 0.063) or SR (-19%, p = 0.053). Total EOM volume decreased by 20%, while globe volume remained unchanged. CAS and proptosis improved post-treatment, but changes in total EOM volume did not significantly correlate with changes in CAS or proptosis. Pre-treatment IR, MR, and SR volumes showed moderate correlation with total EOM volume reduction. Teprotumumab significantly reduces EOM volumes, CAS, and proptosis in TED. Weak correlations with clinical outcomes suggest that additional factors, such as orbital fat, influence treatment response.
6 June 2025 in Ophthalmic Plastic & Reconstructive Surgery
Purpose: This study aimed to describe uncommon cases of ostiomeatal complex (OMC) occlusion and maxillary atelectasis secondary to orbital pathology. Methods: A retrospective chart review of cases of ostiomeatal occlusion and maxillary atelectasis at a single institution was performed. Patients with an identifiable orbital cause were included, whereas patients with idiopathic occlusion (silent sinus syndrome) were excluded. Data collected included patient age, sex, clinical presentation, and measurements including exophthalmolmetry, radiographic features, interventions, and outcomes. Results: Eight patients were identified with mechanical causes of ostiomeatal occlusion arising from the orbit. Five cases had malpositioned orbital floor implants in the setting of remote orbital reconstruction, including after trauma. Two cases had previous orbital decompression for thyroid eye disease with subsequent orbital mucocele and fat prolapse into the OMC. One case had distensible venous malformation of the inferior orbit resulting in occlusion of the OMC. The majority of patients required both endoscopic sinus surgery and treatment of the orbital pathology causing the OMC occlusion. Conclusions: While rare, orbital pathology may cause OMC occlusion, which may lead to maxillary sinus atelectasis. Orbital surgeons should be aware of these associations and have a high index of suspicion when subclinical maxillary atelectasis is seen in conjunction with orbital pathology. Treatment may require addressing the underlying cause as well as multidisciplinary management of both sinus surgery to restore maxillary sinus ventilation and possible orbital reconstruction.
Background: To compare the outcomes of two types of tarsoconjunctival pedicle flaps for reconstruction of large lower eyelid defects. Methods: Retrospective medical record review of consecutive patients who underwent centrally-based or laterally-based tarsoconjunctival pedicle transconjunctival flap for lower eyelid reconstruction for defects greater than 50% of the lid margin. Full thickness skin grafts were used for anterior lamellar reconstruction in all cases. The primary outcome measure was eyelid position, function and satisfactory cosmesis. Results: Forty-three patients were identified. Twenty-six patients underwent reconstruction with a centrally-based tarsoconjunctival pedicle flap; 17 patients underwent reconstruction with a laterally-based tarsoconjunctival pedicle flap. The average size of the lid defect was 77.7% (range 50-100%) in the central group and 75% (range 50-100%) in the lateral group (p=0.604). Mean follow up time was 61.5 weeks in the central group and 46.6 weeks in the lateral group (p=0.765). After division of the flap and during follow up, 27% of the centrally based group required revisional surgery with none in the laterally based group (p=0.03). 100% of the patients with centrally based flaps required second staged division of flap, whereas only 52% of patients with a laterally based flaps underwent second staged flap division. (p<0.001) Conclusion: Outcome suggests that for reconstruction of large lower lid defects requiring lid sharing procedures, both centrally and lateral-based procedures have equivalent functional outcome. However, the laterally based group has less need for revisional procedures and may not need a second stage division of the flap.